Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Mark Edlund is a member of the firm’s Corporate Practice Group and represents clients in corporate transactions, with a focus on domestic and cross-border capital markets transactions. He also advises clients on general corporate matters, including SEC and stock exchange reporting and compliance and corporate governance.

Issuer-side Representation

  • Represented BioNTech SE in its initial public offering.
  • Represented Kadmon Holdings, Inc. in a follow-on offering.

Underwriter-side Representation

  • Represented the underwriters in the initial public offering of Trevi Therapeutics, Inc.
  • Represented the underwriters in the follow-on offerings of UroGen Pharma Ltd., Corbus Pharmaceuticals Holdings, Inc., Zomedica Pharmaceuticals Corp., RedHill Biopharma Ltd., and Zosano Pharma Corporation.
  • Represent the sales agents in several active at-the-market offering programs.